Antibiofilm agents and implant-related infections in orthopaedics: Where are we?

Journal of Chemotherapy

Volumn 25, Issue 2, 2013, Pages 65-80

  Romanò, Carlo L ^a   Toscano, Marco ^b   Romanò, Delia ^a   Drago, Lorenzo ^a,b  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antibiofilm agents; Biofilm; Implant related infections; Infection; Orthopaedics

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADHESIN; ANTIBIOFILM AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BAICALIN; BIOMATERIAL; CELECOXIB; CINNAMALDEHYDE; CITROPIN; DAPTOMYCIN; DEOXYRIBONUCLEASE I; DICLOFENAC; ETODOLAC; FIBRONECTIN BINDING PROTEIN; FURANONE DERIVATIVE; IBUPROFEN; MELOXICAM; MINOCYCLINE; NANOPARTICLE; NIMESULIDE; PHOTOSENSITIZING AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; SERRATIOPEPTIDASE; SORTASE; TIGECYCLINE; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIAL COLONIZATION; BIOFILM; CONFOCAL LASER MICROSCOPY; ESCHERICHIA COLI; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NANOTECHNOLOGY; NONHUMAN; ORTHOPEDIC IMPLANT; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PROSTHESIS INFECTION; QUORUM SENSING; REVIEW; SOFT TISSUE INJURY; CLASSIFICATION; DRUG EFFECT; INFECTION; MICROBIOLOGY; ORTHOPEDIC SURGERY;

ACETYLCYSTEINE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BIOFILMS; HUMANS; NANOTECHNOLOGY; ORTHOPEDIC PROCEDURES; PROSTHESIS-RELATED INFECTIONS;

EID: 84875404429     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000045     Document Type: Review

References (117)

1. Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, Vail TP, et al. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res. 2010;468:45-51.
2. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Sur Am. 2007;89:780-85.
3. Drago L, Romanò CL, Mattina R, Signori V, de Vecchi E. Does Dithiothreitol improve bacterial detection from infected prosthesis? A pilot study. Clin Orthop Relat Res. Epub 2012 Jun 14; doi:10.1007/s11999-012-2415-3.
4. Romanò CL, Romanò D, Bonora C, Degrate A, Mineo G. 'Combined Diagnostic Tool' for joint prosthesis infection. Infez Med. 2009;17:141-50.
5. Hill KE, Malic S, McKee R, Rennison T, Harding KG, Williams DW, et al. An in vitro model of chronic wound biofilms to test wound dressings and assess antimicrobial susceptibilities. J Antimicrob Chemother. 2010;65:1195-206.
6. Zameer F, Gopal S. Evaluation of antibiotic susceptibility in mixed culture biofilms. Intern J Biotech Biochem. 2010;6:93-9.
7. Chen WH, Jiang LS, Dai LY. Influence of bacteria on spinal implant-centered infection: an in vitro and in vivo experimental comparison between Staphylococcus aureus and mycobacterium tuberculosis. Spine. 2011;36:103-8.
8. Stoodley P, Conti SF, DeMeo PJ, Nistico L, Melton-Kreft R, Johnson S, et al. Characterization of a mixed MRSA/MRSE biofilm in an explanted total ankle arthroplasty. FEMS Immunol Med Microbiol. 2001;62:66-74.
9. Arciola CR, Montanaro L, Costerton JW. New trends in diagnosis and control strategies for implant infections. Int J Artif Organs. 2011;34:727-36.
10. Palmer M, Costerton W, Sewecke J, Altman D. Molecular techniques to detect biofilm bacteria in long bone nonunion: A case report. Clin Orthop Relat Res. 2011;469:3037-42.
11. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-22.
12. Shih PC, Huang CT. Effects of quorum-sensing deficiency on Pseudomonas aeruginosa biofilm formation and antibiotic resistance. J Antimicrob Chemother. 2002;49:309-14.
13. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: Its production and regulation. Int J Artif Organs. 2005;28:1062-8.
14. Fernebro J. Fighting bacterial infections-future treatment options. Drug Resist Updat. 2011;14:125-39.
15. Romero D, Kolter R. Will biofilm disassembly agents make it to market? Trends Microbiol. 2011;19:304-6.
16. Poultsides LA, Liaropoulos LL, Malizos KN. The socioeconomic impact of musculoskeletal infections. J Bone Joint Surg Am. 2010;92:e13.
17. Tojo M, Yamashita N, Goldmann DA, Pier GB. Isolation and characterization of a capsular polysaccharide adhesin from Staphylococcus epidermidis. J Infect Dis. 1988;157:713-22.
18. Zhang YQ, Ren SX, Li HL, Wang YX, Fu G, Yang J, et al. Genome-based analysis of virulence genes in a non-biofilmforming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol. 2003;49:1577-93.
19. Nobbs AH, Lamount RJ, Jenkinson H. Streptococcus adherence and colonization. Microbiol Mol Biol Rev. 2009;73:407-505.
20. Marraffini LA, Dedent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of Gram-positive bacteria. Microbiol Mol Biol Rev. 2006;70:192-221.
21. Mazmanian SK, Liu G, Ton-That H, Schneewind O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science. 1999;285:760-3.
22. Montanaro L, Speziale P, Campoccia D, Ravaioli S, Cangini I, Pietrocola G, et al. Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol. 2011;6:1329-49.
23. Marraffini LA, Dedent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of Gram-positive bacteria. Microbiol Mol Biol Rev 2006;70:192-221.
24. Jonsson IM, Mazmanian SK, Schneewind O, Bremell T, Tarkowski A. The role of Staphylococcus aureus sortase A and sortase B in murine arthritis. Microbes Infect. 2003;5:775-80.
25. Weiss WJ, Lenoy E, Murphy T, Tardio L, Burgio O, projan SJ, et al. Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection. J Antimicrob Chemother. 2004;53:480-6.
26. Gianfaldoni C, Maccari S, Pancotto L, Rossi G, Hilleringmann M, Pansegrau W, et al. Sortase A confers protection against Streptococcus pneumoniae in mice. Infect Immun. 2009;77:2957-61.
27. Kim SW, Chang IM, Oh KB. Inhibition of the bacterial surface protein anchoring transpeptidase sortase by medicinal plants. Biosci Biotechnol Biochem. 2002;66:2751-4.
28. Maresso AW, Schneewind O. Sortase as a target of antiinfective therapy. Pharmacol Rev. 2008;60:128-41.
29. Njoroge J, Sperandio V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol Med. 2009;1:201-10.
30. Kaufmann GF, Park J, Janda KD. Bacterial quorum sensing: a new target for anti-infective immunotherapy. Expert Opin Biol Ther. 2008;8:719-24.
31. Tomasz A. Control of the competent state in Pneumococcus by a hormone-like cell product: an example for a new type of regulatory mechanisms in bacteria. Nature. 1965;208:155-9.
32. Manefield M, de Nys R, Kumar N, Read R, Givskov M, Steinberg, et al. Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology. 1999;145:283-91.
33. Lazar V. Quorum sensing in biofilms-how to destroy the bacterial citadels or their cohesion/power? Anaerobe. 2011;17:280-5.
34. Wu H, Song Z, Hentzer M, Andresen JB, Molin S, Givskov M, et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother. 2004;53:1054-61.
35. Hentzer M, Wu H, Andersen JB, Riedel L, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 2003;22:3803-15.
36. Hume EBH, Baveja J, Muir B, Schubert TL, Kumar N, Kjelleberg S, et al. The control of Staphylococcus epidermidis biofilm formation and in vivo infection rates by covalently bound furanones. Biomaterials. 2004;25:5023-30.
37. Kiran MD, Giacometti A, Cirioni O, Balaban N. Suppression of biofilm related, device-associated infections by staphylococcal quorum sensing inhibitors. Int J Artif Organs. 2008;31:761-70.
38. Balaban N, Goldkorn T, Nhan RT, Dang LB, Scott S, Ridgley RM, et al. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science. 1998;280:438-40.
39. Giacometti A, Cirioni O, Gov Y, Ghiselli R, Del Prete MS, Mocchegiani F, et al. RNAIII inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2003;47:1979-83.
40. Anguita-Alonso P, Giacometti A, Cirioni O, Ghiselli R, Orlando F, Saba V, et al. RNAIII-inhibiting-peptide loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation. Antimicrob. Agents Chemother. 1998;51:2594-6.
41. Lovetri K, Madhyastha S. Antimicrobial and antibiofilm activity of quorum sensing peptides and Peptide analogues against oral biofilm bacteria. Methods Mol Biol. 2010;618:383-92.
42. Cirioni O, Ghiselli R, Minardi D, Orlando F, Mocchegiani F, Silvestri C, et al. RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infection. Antimicrob. Agents Chemother. 2007;51:4518-20.
43. Geske GD, Wezeman RJ, Siegel AP, Blackwell HE. Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J Am Chem Soc. 2005;127:12762-3.
44. Kaufmann GF, Sartorio R, Lee SH, Mee JM, Altobell LJ 3rd, Kujawa DP, et al. Antibody interference with Nacyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc. 2006;128:2802-3.
45. Musk DJ Jr, Hergenrother PJ. Chemical countermeasures for the control of bacterial biofilms: effective compounds and promising targets. Curr Med Chem. 2006;13:2163-77.
46. Pan JC, Ren DC. Quorum sensing inhibitors: a patent review. Expert Opin Ther Patents. 2009;19:1581-601.
47. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother. 2011;55:2655-61.
48. Christensen LD, van Gennip M, Jakobsen TH, Alhede M, Hougen HP, Høiby N, Bjarnsholt T, Givskov M. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother. 2012;67(5):1198-206.
49. Farber BF, Wolff AG. The use of nonsteroidal antiinflammatory drugs to prevent adherence of Staphylococcus epidermidis to medical polymers. J Infect Dis. 1992;166:861-5.
50. Alem MA, Douglas J. Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother. 2004;1:41-7.
51. del Prado G, Ruiz V, Naves P, Rodrìguez-Cerrato V, Soriano F, del Carmen Ponte M. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-L-cysteine, amoxicillin, erythromycin, and levofloxacin. Diagn Microbiol Infect Dis. 2010;67:311-8.
52. Naves P, del Prado G, Huelves L, Rodrìguez-Cerrato V, Ruiz V, Ponte MC, et al. Effects of human serum albumin, ibuprofen and N-acetyl-L-cysteine against biofilm formation by pathogenic Escherichia coli strains. J Hosp Infect. 2010;76:165-70.
53. Drago L, de Vecchi E, Nicola L, Valli M, Gismondo MR. Effects of subinhibitory concentrations of ibuprofen isobuthanolammonium on virulence factors of uropathogenic Escherichia coli. J Chemother. 2002;14:314-5.
54. Héquet A, Humblot V, Berjeaud JM, Pradier CM. Optimized grafting of antimicrobial peptides on stainless steel surface and biofilm resistance tests. Colloids Surf B Biointerfaces. 2011;84:301-9.
55. Willcox MD, Hume EB, Aliwarga Y, Kumar N, Cole N. A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. J Appl Microbiol. 2008;105:1817-25.
56. Cole N, Hume EB, Vijay AK, Sankaridurg P, Kumar N, Willcox MD. In vivo performance of melimine as an antimicrobial coating for contact lenses in models of CLARE and CLPU. Invest Ophthalmol Vis Sci. 2010;51:390-5
57. Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Orlando F, Mocchegiani F, et al. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides. 2006;27:1210-6.
58. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322-32.
59. Park SC, Park Y, Hahm KS. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int J Mol Sci. 2011;12:5971-92.
60. Eckert R, Qi F, Yarbrough DK, He J, Anderson MH, Shi W. Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob Agents Chemother. 2006;50:1480-8.
61. He J, Anderson MH, Shi W, Eckert R. Design and activity of a 'dual-targeted' antimicrobial peptide. Int J Antimicrob Agents. 2009;33:532-7.
62. Li YH, Huang S, Du M, Bian Z, Chen Z, Fan MW. Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime-protein boost immunization. Vaccine. 2010;28:5370-6.
63. Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MC. Proteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Chemother. 1993;37:2618-21.
64. Artini M, Scoarughi GL, Papa R, Cellini A, Carpentieri A, Pucci P, et al. A new anti-infective strategy to reduce adhesionmediated virulence in Staphylococcus aureus affecting surface proteins. Int J Immunopathol Pharmacol. 2011;24:661-72.
65. Mecikoglu M, Saygi B, Yildirim Y, Karadag-Saygi E, Ramadan SS, Esemenli T. The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implantrelated infection. J Bone Joint Surg Am. 2006;88:1208-14.
66. Kaplan JB, Lovetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot. 2012;65(2):73-7.
67. Kaplan JB. Therapeutic potential of biofilm-dispersing enzymes. Int J Artif Organs. 2009;32:545-54.
68. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Efficacy of combination of chlorhexidine and protamine sulphate against device-associated pathogens. J Antimicrob Chemother. 2008;61:651-7.
69. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother. 2009; 64:88-93.
70. Harris LG, Bexfield A, Nigam Y, Rohde H, Ratcliffe NA, Mack D. Disruption of Staphylococcus epidermidis biofilms by medicinal maggot Lucilia sericata excretions/secretions. Int J Artif Organs. 2009;32:555-64.
71. Cazander G, van de Veerdonk MC, Vandenbroucke-Grauls CM, Schreurs MW, Jukema GN. Maggot excretions inhibit biofilm formation on biomaterials. Clin Orthop Relat Res. 2010;468(10):2789-96.
72. Sheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann NY Acad Sci. 1963;106:298-310.
73. Zygmunt, WA, Martin TA. Cysteine analogs as potential amino acid antagonists in bacteria. JMed Chem. 1968;11:623-5.
74. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, Hurtado C, Blanco MT, Gòmez-Garcìa AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997;39:643-6.
75. Olofsson AC, Hermansson M, Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol. 2003;69:4814-22.
76. Mansouri MD, Darouiche RO. In vitro antimicrobial activity of Nacetylcysteine against bacteria colonising central venous catheters. Int J Antimicrob Agents. 2007;29:474-6.
77. Schwandt LQ, van Weissenbruch R, Stokroos I, van der Mei HC, Busscher HJ, Albers FW. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat. Acta Otolaryngol. 2004;124:726-31.
78. Aslam S, Darouiche RO. Role of antibiofilm-antimicrobial agents in controlling device-related infections. Int J Artif Organs. 2011;34:752-8.
79. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Intern J Antimicrob Agent. 2003;22:S95-S100.
80. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother. 2007;51:1556-8.
81. El-Feky MA, El-Rehewy MS, Hassan MA, Abolella HA, Abd El-Baky RM, Gad GF. Effect of ciprofloxacin and Nacetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Pol J Microbiol. 2009;58:261-7.
82. Zhao T, Liu Y. RN-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010;10:140-8.
83. Stewart PS, McFeters GA, Huang CT. Biofilm control by antimicrobial agents. In: Bryers JD, eiditor. Biofilm: process analysis and applications. New York: Wiley-Liss; 2000. p. 373-405.
84. Brown MR, Allison DG, Gilbert P. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J Antimicrob Chemother. 1988;22:777-80.
85. Kim L. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5:48-56.
86. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45:999-1007.
87. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature. 2002;416:740-3.
88. Darouiche RO, Dhir A, Miller AJ, Landon GC, Raad II, Musher DM. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J Infect Dis. 1994;170:720-3.
89. Gattringer KB, Suchomel M, Eder M, Lassnigg AM, Graninger W, Presterl E. Time-dependent effects of rifampicin on staphylococcal biofilms. Int J Artif Organs. 2010;33:621-6.
90. Hansen LK, Berg K, Johnson D, Sanders, Citron M. Efficacy of local rifampin/minocycline delivery (AIGIS(RX)R) to eliminate biofilm formation on implanted pacing devices in a rabbit model. Int J Artif Organs. 2010;33:627-35.
91. Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656-60.
92. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother. 2007;51:78-83.
93. Cirioni O, Mocchegiani F, Ghiselli R, Silvstri C, Gabrielli E, Marchionni E, et al. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of Staphylococcal infection. Eur J Vasc Endovasc Surg. 2010;40:817-22.
94. Coenye T, Nelis HJ. In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods. 2010;83:89-105.
95. Jori G. Photodynamic therapy of microbial infections: state of the art and perspectives. J Environ Pathol Toxicol Oncol. 2006;25:505-19.
96. Di Poto A, Sbarra MS, Provenza G, Visai L, Speziale P. The effect of photodynamic treatment combined with antibiotic action or host defence mechanisms on Staphylococcus aureus biofilms. Biomaterials. 2009;30:3158-66.
97. Sharma M, Visai L, Bragheri F, Cristiani I, Gupta PK, Speziale P. Toluidine blue-mediated photodynamic effects on staphylococcal biofilms. Antimicrob Agents Chemother. 2008;52:299-305.
98. Vilela SF, Junqueira JC, Barbosa JO, Majewski M, Munin E, Jorge AO. Photodynamic inactivation of Staphylococcus aureus and Escherichia coli biofilms by malachite green and phenothiazine dyes: An in vitro study. Arch Oral Biol. 2011;57:704-710.
99. Saino E, SbarraMS, Arciola CR, ScaloneM, Bloise N, Nikolov P, et al. Photodynamic action of Tri-meso (N-methyl-pyridyl), meso (N-tetradecyl-pyridyl) porphine on Staphylococcus epidermidis biofilms grown on Ti6Al4V alloy. Int J Artif Organs. 2010;33:636-45.
100. Poggio C, Arciola CR, Dagna A, Floridi F, Chiesa M, Saino E, et al. Photoactivated disinfection (PAD) in endodontics: an in vitro microbiological evaluation. Int J Artif Organs. 2011;34:889-97.
101. Maisch T. Anti-microbial photodynamic therapy: useful in the future? Lasers Med Sci. 2007;22:83-91.
102. Abdelghany SM, Quinn DJ, Ingram RJ, Gilmore BF, Donnelly RF, Taggart CC, Scott CJ. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomedicine. 2012;7:4053-63.
103. Vukomanović M, Skapin SD, Poljansěk I, Zagar E, Kralj B, Ignjatović N, Uskoković D. oly(D, L-lactide-co-glycolide)/ hydroxyapatite core-shell nanosphere. Part 2: simultaneous release of a drug and a prodrug (clindamycin and clindamycin phosphate). Colloids Surf B Biointerfaces. 2011;82(2):414-21.
104. Burygin GL, Khlebtsov BN, Shantrokha AN, Dykman LA, Bogatyrev VA, Khlebtsov NG. On the enhanced antibacterial activity of antibiotics mixed with gold nanoparticles. Nanoscale Res Lett. 2009;4(8):794-801.
105. Taylor E, Webster TJ. Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine. 2011;6:1463-73.
106. Artini M, Romanò CL, Manzoli L, Scoarughi GL, Papa R, Meani E, et al. Staphylococcal IgM enzyme-linked immunosorbent assay for diagnosis of periprosthetic joint infections. J Clin Microbiol. 2011;49(1):423--5.
107. Watson DL. Serological response of sheep to live and killed Staphylococcus aureus vaccines. Vaccine 1987;5:275-8.
108. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491-6.
109. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun. 2011;79:1797-803.
110. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect Immun. 2006;74:3415-26.
111. Park J. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol. 2007;14(10):1119-27.
112. Arciola CR. New concepts and new weapons in implant infections. Int J Artif Organs. 2009;32:533-6.
113. Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci. 2011;1241:104-21.
114. Boles BR, Horswill AR. Staphylococcal biofilm disassembly. Trends Microbiol. 2011;19:449-55.
115. Lönn-Stensrud J, Landin MA, Benneche T, Petersen FC, Scheie AA. Furanones, potential agents for preventing Staphylococcus epidermidis biofilm infections? J Antimicrob Chemother. 2009;63(2):309-16.
116. Kim PJ, Steinberg JS. Wound care: biofilm and its impact on the latest treatment modalities for ulcerations of the diabetic foot. Semin Vasc Surg. 2012;25(2):70-4.
117. Khan S, Tøndervik A, Sletta H, Klinkenberg G, Emanuel C, Onsøyen E, et al. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. Antimicrob Agents Chemother. Epub 2012 Lul 23; doi:10.1128/AAC.00525-12.